Protalix 
Welcome,         Profile    Billing    Logout  
 5 Products   1 Disease  5 Products   6 Trials   262 News 
8 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Elfabrio (pegunigalsidase alfa-iwxj) / Protalix, Chiesi
Bright51, NCT03614234 / 2018-001947-30: Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients

Active, not recruiting
3
29
Europe, US, RoW
pegunigalsidase alfa, PRX-102
Chiesi Farmaceutici S.p.A.
Fabry Disease
12/25
03/26
NCT03566017 / 2018-001148-67: Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease

Completed
3
97
Europe, Canada, US, RoW
pegunigalsidase alfa, PRX-102
Chiesi Farmaceutici S.p.A.
Fabry Disease
01/25
01/25
FLY, NCT06328608: A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

Recruiting
2/3
22
Europe, US
PRX-102 1 mg/kg every two weeks, pegunigalsidase alfa, Recombinant human alpha galactosidase-A
Chiesi Farmaceutici S.p.A., ICON plc
Fabry Disease
12/27
03/28
RISE, NCT05710692: Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease

Recruiting
2/3
18
Japan
PRX-102 1 mg/kg every 2 weeks, pegunigalsidase alfa, Recombinant human alpha galactosidase-A, PRX-102 2 mg/kg every 4 weeks
Chiesi Farmaceutici S.p.A., ICON plc
Fabry Disease
03/26
03/28
NCT04552691: Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients

Approved for marketing
N/A
US
Pegunigalsidase Alfa
Chiesi Farmaceutici S.p.A., Chiesi USA, Inc.
Fabry Disease
 
 
MODERN, NCT06663358: A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients

Recruiting
N/A
100
US
Pegunigalsidase-alfa, Elfabrio®
Chiesi Farmaceutici S.p.A.
Fabry Disease
11/29
11/29
MOS, NCT06941025: Maternal and Postnatal Outcomes Study (): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

Not yet recruiting
N/A
10
Europe, US
Not applicable- observational study
Chiesi Farmaceutici S.p.A., ICON plc
Fabry Disease, Pregnancy, Pregnancy Complications
12/34
12/34
GoPEG, NCT06095713: German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa

Recruiting
N/A
60
Europe
Pegunigalsidase-alfa
Universität Münster, Chiesi GmbH
Fabry Disease
09/27
09/27
PRX-107 / Protalix
No trials found
AIR DNAse (alidornase alfa) / SarcoMed
No trials found
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Elfabrio (pegunigalsidase alfa-iwxj) / Protalix, Chiesi
Bright51, NCT03614234 / 2018-001947-30: Open Label Extension of 2 mg/kg Pegunigalsidase Alfa (PRX-102) Every 4 Weeks in Adult Fabry Disease Patients

Active, not recruiting
3
29
Europe, US, RoW
pegunigalsidase alfa, PRX-102
Chiesi Farmaceutici S.p.A.
Fabry Disease
12/25
03/26
NCT03566017 / 2018-001148-67: Open Label Extension Study of 1 mg/kg Pegunigalsidase Alfa Every 2 Weeks in Patients With Fabry Disease

Completed
3
97
Europe, Canada, US, RoW
pegunigalsidase alfa, PRX-102
Chiesi Farmaceutici S.p.A.
Fabry Disease
01/25
01/25
FLY, NCT06328608: A Study to Learn About the Safety and Effects of the Study Drug PRX-102 in Children and Adolescents With Fabry Disease

Recruiting
2/3
22
Europe, US
PRX-102 1 mg/kg every two weeks, pegunigalsidase alfa, Recombinant human alpha galactosidase-A
Chiesi Farmaceutici S.p.A., ICON plc
Fabry Disease
12/27
03/28
RISE, NCT05710692: Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease

Recruiting
2/3
18
Japan
PRX-102 1 mg/kg every 2 weeks, pegunigalsidase alfa, Recombinant human alpha galactosidase-A, PRX-102 2 mg/kg every 4 weeks
Chiesi Farmaceutici S.p.A., ICON plc
Fabry Disease
03/26
03/28
NCT04552691: Open-Label Expanded Access Treatment With Pegunigalsidase Alfa for Fabry Disease Patients

Approved for marketing
N/A
US
Pegunigalsidase Alfa
Chiesi Farmaceutici S.p.A., Chiesi USA, Inc.
Fabry Disease
 
 
MODERN, NCT06663358: A Multi-Country Observational Study of Safety and Effectiveness of Elfabrio® in Fabry Patients

Recruiting
N/A
100
US
Pegunigalsidase-alfa, Elfabrio®
Chiesi Farmaceutici S.p.A.
Fabry Disease
11/29
11/29
MOS, NCT06941025: Maternal and Postnatal Outcomes Study (): A Global Observational Registry Assessing the Safety of Elfabrio® in Women With Fabry Disease and Their Infants During Pregnancy and Breastfeeding

Not yet recruiting
N/A
10
Europe, US
Not applicable- observational study
Chiesi Farmaceutici S.p.A., ICON plc
Fabry Disease, Pregnancy, Pregnancy Complications
12/34
12/34
GoPEG, NCT06095713: German Observational Multicenter Study of Patients With Fabry Disease Under Enzyme Replacement Therapy With Pegunigalsidase-alfa

Recruiting
N/A
60
Europe
Pegunigalsidase-alfa
Universität Münster, Chiesi GmbH
Fabry Disease
09/27
09/27
PRX-107 / Protalix
No trials found
AIR DNAse (alidornase alfa) / SarcoMed
No trials found

Download Options